Galmed Pharmaceuticals Q3 2025 cash and equivalents up 25% to USD 19.2 million
Galmed Pharmaceuticals reported a 25% increase in cash and equivalents to USD 19.2 million for Q3 2025. Research and development expenses were USD 1.1 million, and general and administrative expenses were USD 1.0 million, totaling USD 2.1 million in operating expenses for the quarter. For the nine months, operating expenses were USD 5.5 million. Financial income was negative USD 0.2 million for Q3 and negative USD 0.5 million for the nine months. An impairment of associate of USD 0.5 million was recorded for the nine months.
Galmed Pharmaceuticals Ltd. reported its financial results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, research and development expenses totaled 1.1 million, while general and administrative expenses were 1.0 million. Total operating expenses for the quarter amounted to 2.1 million. For the nine-month period, research and development expenses reached 2.8 million, and general and administrative expenses were 2.7 million. Total operating expenses for the nine months were 5.5 million. As of September 30, 2025, cash and cash equivalents, short-term deposits, restricted cash, and marketable debt securities totaled 19.2 million. This represents an increase of 25 percent compared to December 31, 2024. Financial income, net, for Q3 2025 was negative 0.2 million, and for the nine-month period, it was negative 0.5 million. For the nine months ended September 30, 2025, an impairment of associate of 0.5 million was recorded. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33361) on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
